



NZX/ASX Announcement

23 September 2026

UNITAID response to TruScreen's Global Cervical Cancer Elimination Grant Proposals

TruScreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) advises that the three proposals submitted in April 2026 in response to global funder UNITAID's Call for Proposals: *Accelerating Cervical Cancer Elimination through Secondary Prevention in Low and Middle Income Countries*, were not selected for further development on this occasion. TruScreen's efforts and engagement in responding to their Call for Proposals were acknowledged, and the Company was encouraged to respond to future cervical cancer elimination Calls for Proposals.

The April 2026 proposals were:

- **Proposal 1: Sub Saharan Africa Scale-Up** – a 36-month scale-up of TruScreen as a standalone AI-enabled screening tool across six African countries, Zimbabwe, South Africa, Eswatini, Rwanda, Nigeria, and Kenya
- **Proposal 2: African Screen-and-Treat Programme** – a transformative proposal to introduce a same-visit screen-and-treat model across the same six African countries
- **Proposal 3: Asia-Pacific & Latin America Scale up** – a proposal to address the cervical cancer crisis Asia-Pacific and Latin America, in China, India, Indonesia, Vietnam, Uzbekistan, Mexico, Malaysia, and Thailand

While these TruScreen led proposals would not proceed, their development strengthened key relationships with a consortium of internationally recognised implementation NGO partners, with which the Company intends to partner with in the future. We believe that TruScreen's cervical cancer screening technology is ideally suited for Low and Middle income countries. We will continue to market our technology to contribute to the WHO 90-70-90 cervical cancer elimination strategy with the successful recipients of the UNITAID grant funding.

TruScreen is also the technology provider to a **UNITAID** grant application by a global NGO, which remains under consideration

There is also a grant proposal under consideration by the **Clinton Health Access Initiative (CHAI)** that included the following partners:

- **National AIDS Council of Zimbabwe (NAC)** - the apex body responsible for coordinating Zimbabwe's national response to HIV and AIDS, with which TruScreen has maintained a formal partnership since 2022
- **PATH** - a global nonprofit organisation that drives transformative innovation in health to save lives.
- **Solina Centre for International Development and Research (SCIDaR)** - a Nigerian nonprofit institution within the Solina Group, dedicated to accelerating positive health, social, and economic reforms through high-quality programme design, implementation, and capacity building



- **RedAid Nigeria** - a Nigerian community health organisation with a strong presence in primary and community-level health service delivery.
- **Baylor College of Medicine Children's Foundation Eswatini** - the national leader in paediatric HIV/AIDS and tuberculosis care in one of the world's most heavily HIV-affected countries.

TruScreen's African expansion continues at pace. Nigeria will have TruScreen's first African reference clinic with training already completed for a 300 patient clinical evaluation. This will support the application for TruScreen's inclusion in the Nigerian national screening guideline and government screening programs. Nigerian regulatory product approval is expected to take 3 to 6 months. According to the WHO GLOBOCAN 2024 estimate Nigeria's estimated cervical-cancer burden remains materially higher than the global average: approximately **23.9 new cases** and **14.1 deaths per 100,000 women annually**, versus the global figures of **12.4** and **5.5**, respectively. WHO estimates that 12,312 Nigerian women will contract cervical cancer and 7,599 Nigerian women will die from cervical cancer each year.

ZeroCancer Professional Consult Limited (ZPC) is the appointed TruScreen distributor for Nigeria, Ghana, and Côte d'Ivoire.

TruScreen is also the selected screening technology for two other Nigeria-specific grant applications pending final decisions, led by **Dr Ayokunle Olumodeji** from **Lagos State University Teaching Hospital (LASUTH)** and **Lagos State University College of Medicine (LASUCOM)**.

These grant applications are:

- **Gates Foundation's Grand Challenges:** Innovations in Cost-Disruptive Tools for Diagnosis and Screening (OPP12345) program
- **Beginning Investigator Grant for Catalytic Research (BIG Cat)** - supported by American Association for Cancer Research

In summary, TruScreen has the following 'live' grant applications which should be announced by 31 December 2026.

1. Collaboration with a global NGO for a UNITAID funding multi-country program
2. Clinton Health Access Initiative African program
3. Gates Foundation Grand Challenges
4. BIG CAT

We will continue to advise the market of the outcomes of these grant applications.

Authorised by the Board for filing with the NZX/ASX.

For more information, visit www.truscreen.com or contact:

Martin Dillon, CEO
martindillon@truscreen.com

Guy Robertson, Chief Financial Officer
guyrobertson@truscreen.com



About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer". To learn more, please visit: www.truscreen.com/.

**Based on Single Use Sensor sales.*

About DaltonBio:

DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening. Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk types of HPV and cervical cancer screening.

DALTONbio's exceptional, clinically proven products have served tens of millions of lives in the world. They have aided health professionals in detecting, diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere, every day. To learn more, please visit: www.daltonbio.com/.